Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

3 Study Matches

Site for HEALEY ALS Platform Trial - Master Protocol

The HEALEY ALS Platform Trial is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. The trial is designed as a perpetual platform trial. This means that there is a single Master Protocol determining the conduct of the trial.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04297683
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with amyotrophic lateral sclerosis (ALS)
Slow vital capacity (SVC) at least 50% predicted
Time since onset of weakness due to ALS within 36 months
Able to swallow pills and liquids
Exclusion Criteria:
Exposure at any time to any gene therapies under investigation for the treatment of ALS
Clinically significant unstable medical condition (other than ALS) that would pose a risk to you
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Therapy in Amyotrophic Lateral Sclerosis (TAME)

This is a phase IIB multi-centered, double blind, placebo controlled study to assess the safety and efficacy of a medication called memantine in people with ALS. This study is designed to validate the preliminary data that suggests memantine can slow down the course of ALS and also to determine if memantine can improve ALS patients who have characteristics of frontotemporal dementia.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02118727
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-85
Diagnosed with amyotrophic lateral sclerosis (ALS)
ALS Functional Rating Scale (ALSFRS-R) score > 25
Has a caregiver willing to help with study activities
Exclusion Criteria:
Forced vital capacity (FVC) ≤ 60% predicted
ALS-related weakness for more than 3 years
History of liver disease
Kidney failure
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04165824
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Exclusion Criteria:
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA